BR9703874A - Agente para profilaxia e tratamento de distúrbios da função visual - Google Patents

Agente para profilaxia e tratamento de distúrbios da função visual

Info

Publication number
BR9703874A
BR9703874A BR9703874A BR9703874A BR9703874A BR 9703874 A BR9703874 A BR 9703874A BR 9703874 A BR9703874 A BR 9703874A BR 9703874 A BR9703874 A BR 9703874A BR 9703874 A BR9703874 A BR 9703874A
Authority
BR
Brazil
Prior art keywords
prophylaxis
agent
treatment
visual function
function disorders
Prior art date
Application number
BR9703874A
Other languages
English (en)
Inventor
Noriko Watanabe
Takahiro Ogawa
Mitsuyoshi Isaka
Toshiharu Tsuboi
Mitsunori Waki
Original Assignee
Takeda Chemical Industries Ltd
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Senju Pharma Co filed Critical Takeda Chemical Industries Ltd
Publication of BR9703874A publication Critical patent/BR9703874A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR9703874A 1996-07-05 1997-07-07 Agente para profilaxia e tratamento de distúrbios da função visual BR9703874A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17693396 1996-07-05
JP21394196 1996-08-13
JP31403396 1996-11-25

Publications (1)

Publication Number Publication Date
BR9703874A true BR9703874A (pt) 1998-09-01

Family

ID=27324333

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9703874A BR9703874A (pt) 1996-07-05 1997-07-07 Agente para profilaxia e tratamento de distúrbios da função visual

Country Status (9)

Country Link
US (1) US5952338A (pt)
EP (1) EP0819431A1 (pt)
KR (1) KR980008226A (pt)
CN (1) CN1172644A (pt)
AU (1) AU2843397A (pt)
BR (1) BR9703874A (pt)
CA (1) CA2209581A1 (pt)
HU (1) HUP9701150A2 (pt)
ID (1) ID17647A (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP1338596B1 (en) * 2000-11-20 2006-01-11 Sankyo Company, Limited processes for the preparation of carbapenem-type antibacterial agents
WO2002078673A1 (fr) * 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
WO2002078669A1 (fr) * 2001-03-30 2002-10-10 Takeda Chemical Industries, Ltd. Solutions medicinales
JP2003010158A (ja) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc 眼精疲労モデル、その作製方法、そのモデルを用いた評価方法およびその評価法を用いて選択された薬剤
FR2863496A1 (fr) * 2003-12-12 2005-06-17 Anben Pharma Composition therapeutique destinee au traitement des troubles de l'accomodation de l'oeil humain
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4143042A (en) * 1977-03-08 1979-03-06 Takeda Chemical Industries, Ltd. 1-azaxanthone-3-carboxylic acids
US4299963A (en) * 1977-03-08 1981-11-10 Takeda Chemical Industries, Ltd. 1-Azaxanthone derivatives
US4255576A (en) * 1977-03-08 1981-03-10 Takeda Chemical Industries, Ltd. 1-Azaxanthone derivatives
CA1095519A (en) * 1977-03-14 1981-02-10 Harold E. Zaugg Esters of 1,4-ethano-10-hydroxy-5-oxo-5h-[1] benzopyrano [3,4-b] pyridine
JPS5825677B2 (ja) * 1977-09-26 1983-05-28 武田薬品工業株式会社 3−テトラゾ−ル−1−アザキサントン誘導体およびその製造法
JPS6110588A (ja) * 1985-01-23 1986-01-18 Takeda Chem Ind Ltd 1−アザキサントン誘導体およびその製造法
JPS6110587A (ja) * 1985-01-23 1986-01-18 Takeda Chem Ind Ltd 1−アザキサントン−3−カルボン酸誘導体およびその製造法
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US5519030A (en) * 1993-10-07 1996-05-21 Senju Pharmaceutical Co., Ltd. Method for prophylaxis and treatment of myopia

Also Published As

Publication number Publication date
HUP9701150A2 (hu) 1999-02-01
US5952338A (en) 1999-09-14
HU9701150D0 (en) 1997-09-29
ID17647A (id) 1998-01-15
CA2209581A1 (en) 1998-01-05
KR980008226A (ko) 1998-04-30
EP0819431A1 (en) 1998-01-21
AU2843397A (en) 1998-01-15
MX9705077A (es) 1998-05-31
CN1172644A (zh) 1998-02-11

Similar Documents

Publication Publication Date Title
BR9702541A (pt) Composição cosmética e/ou dermatológica utilização da composição e processo para tratamento não-terapêutico cosmético
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
EP0776210A4 (en) METHOD FOR PROPHYLAXIS AND / OR TREATMENT OF PROLIFERATIVE AND / OR INFLAMMATORY CONDITIONS OF THE SKIN
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
HK1037303A1 (en) Compositions and methods for treatment of mitochondrial diseases
BR9406178A (pt) Composição de amino-açucar e glicosaminoglicano para o tratamento e restauração de tecido conectivo
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
AU2209697A (en) Fluorocarbons for diagnosis and treatment of articular disorders
BR9504072A (pt) Composiçao farmacêutica métodos para o tratamento de hipercolesterolemia de aterosclerose e kit
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
BR9604959A (pt) Composição e método para o tratamento de desensibilização de dentes
PT928193E (pt) Utilizacao de 1-hidroxi-2-piridonas para o tratamento de infeccoes da pele
BR9703874A (pt) Agente para profilaxia e tratamento de distúrbios da função visual
BR9705049A (pt) Agente para tratamento de cabelo com propriedades de fixação duradouras
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
PT928183E (pt) Utilizacao de 1-hidroxilo-2-piridoneno para o tratamento da dermatite seborroica
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
BR9606925A (pt) Utilização de compostos e processo para o tratamento e profilaxia da obesidade
PT918521E (pt) Formulacao para o tratamento e/ou profilaxia da demencia
BR9606754A (pt) Uso de compostos processo para tratamento e profilaxia de ginecomastia idiopática ou fisiológia e novo detalhe característico ou combinação de detalhes

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]